{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-24-017271","form_type":"8-K","ticker":null,"cik":"0001522860","company_name":"Acutus Medical, Inc.","filed_at":"2024-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.682275+00:00","generated_at":"2026-05-29T08:36:40.208159+00:00","sec_items":["2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Acutus Medical cuts 70% workforce (~61 employees) and transitions CEO to consulting role","bullets":["Workforce reduction of ~61 employees (~70%) expected to be completed by Q1 2025.","Pre-tax exit charges estimated $1.4M-$1.8M; majority cash outlay in Q1 2025.","CEO Takeo Mukai shifts to consulting role Feb 2025, retains titles, receives $10k/month.","Company scales down to only support Medtronic left-heart access obligations; earnout potential until 2027.","Cash on hand $12.6M as of Sep 30, 2024, expected to fund remaining business."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-24-017271","json":"https://secwatch.observer/filing/0000950103-24-017271.json","markdown":"https://secwatch.observer/filing/0000950103-24-017271.md","text":"https://secwatch.observer/filing/0000950103-24-017271.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1522860/000095010324017271/0000950103-24-017271-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1522860/000095010324017271/dp221457_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T08:36:40.208159+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c4e9beddf0eace8ea74753e9fc3d1f9818993348","claim":"Acutus Medical, Inc. announced a restructuring with charges of approximately $1.4 million to $1.8 million of pre-tax downsizing and exit-related charges affecting left-heart access manufacturing and distribution business (approximately 61 employees, representing approximately 70% of the Company's employees).","evidence_excerpt":"The Company estimates it will incur approximately $1.4 million to $1.8 million of pre-tax downsizing and exit-related charges, of which approximately $0.3 million represents future cash expenditures for the payment of monetary consideration and related benefit costs, approximately $1.2 million represents future cash expenditures for the payment of retention bonuses to certain employees that will assist with the Downsizing, and potentially up to $0.3 million estimated as future cash expenditures for contract closing costs.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1522860/000095010324017271/0000950103-24-017271-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.4 million to $1.8 million of pre-tax downsizing and exit-related charges"},{"label":"Affected area","value":"left-heart access manufacturing and distribution business"},{"label":"Headcount","value":"approximately 61 employees, representing approximately 70% of the Company's employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}